Back HIV/AIDS

HIV / AIDS

HIV Glasgow: Long-Acting HIV Fusion Inhibitor Albuvirtide Regimen Matches Standard Therapy

A new fusion inhibitor, albuvirtide, under development in China, combined with a boosted protease inhibitor, proved just as effective as a triple regimen of lopinavir/ritonavir plus 2 NRTIs for treatment-experienced HIV patients, according to a report at the International Congress on Drug Therapy in HIV Infection last month in Glasgow.

alt

HIV Glasgow: Darunavir/Ritonavir + Lamivudine Matches Triple-Drug HIV Therapy

Simplifying antiretroviral therapy to a 2-drug combination of lamivudine plus the protease inhibitor darunavir (Prezista) boosted by ritonavir is just as effective as a 3-drug regimen in people with suppressed viral load, Spanish investigators reported at the International Congress on Drug Therapy in HIV infection (HIV Glasgow) last month in Glasgow.

alt

IDWeek 2016: Omega-3 Fatty Acids May Improve Triglycerides and Inflammation in HIV+ People

Long-term use of omega-3 fatty acid supplements was associated with reduced levels of triglycerides and the inflammation biomarker C-reactive protein (CRP) in HIV-positive people with suppressed viral load, according to research presented last week at IDWeek 2016 in New Orleans.

alt

HIV-Positive People May Lose More Years of Life from Smoking than from HIV/AIDS

People with HIV on effective antiretroviral treatment who smoke cigarettes may incur more risk of death and reduction in life expectancy from smoking than from HIV/AIDS-related conditions, according to a study described in the November 3 advance edition of the Journal of Infectious Diseases.

alt

Coverage of IDWeek 2016

HIVandHepatitis.com coverage of IDWeek 2016, held October 26-30 in New Orleans.

Conference highlights include experimental HIV therapies, PrEP and other biomedical HIV prevention, antibiotic resistance, and emerging infectious diseases such as Ebola virus and Zika virus.

Full listing of coverage by topic

IDWeek website

11/4/16

alt

 

IDWeek 2016: Tenofovir Alafenamide Works Well and Improves Kidney and Bone Markers in Older HIV Patients

A coformulation of tenofovir alafenamide (TAF) plus emtricitabine, used with a third antiretroviral drug, maintained viral suppression as well as tenofovir disoproxil fumarate (TDF) plus emtricitabine in older individuals, and was associated with improvements in kidney function and bone density, which may be of greater concern for this group, according to a presentation last week at IDWeek 2106 in New Orleans.

alt

Coverage of HIV Drug Therapy Glasgow 2016

HIVandHepatitis.com coverage of the 2016 International Congress on Drug Therapy in HIV Infection, held  October 23-26, 2016, in Glasgow, Scotland.

Conference highlights include new antiretroviral therapies and strategies, HIV prevention, HIV-related comorbidities, and expanding access to treatment.

Full listing of coverage by topic

HIV Drug Therapy 2016 website

11/4/16

alt